Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2012
At a glance
- Drugs LY 2886721 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- 10 Jun 2017 Biomarkers information updated
- 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
- 25 Nov 2010 Status changed from recruiting to completed.